We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Molecular Biometrics to Demonstrate Biospectroscopy-Based Metabolomics Technology for IVF at ESHRE Annual Meeting
Product News

Molecular Biometrics to Demonstrate Biospectroscopy-Based Metabolomics Technology for IVF at ESHRE Annual Meeting

Molecular Biometrics to Demonstrate Biospectroscopy-Based Metabolomics Technology for IVF at ESHRE Annual Meeting
Product News

Molecular Biometrics to Demonstrate Biospectroscopy-Based Metabolomics Technology for IVF at ESHRE Annual Meeting


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Molecular Biometrics to Demonstrate Biospectroscopy-Based Metabolomics Technology for IVF at ESHRE Annual Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Molecular Biometrics (MB) has announced that researchers will present results of three clinical studies investigating the use of ViaTest™-E, the Company's non-invasive platform designed to assess embryo and gamete viability in IVF. ViaTest-E was developed using Molecular Biometrics' technology of biospectroscopy-based metabolomics (BSM™).

The results of these studies will be presented at the 23rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Lyon, France (July 1 - 4, 2007). Molecular Biometrics will also exhibit at ESHRE, where it will demonstrate the Company's BSM System prototype.

James Posillico, Ph.D., President and CEO of Molecular Biometrics commented, "Molecular Biometrics plans to offer IVF practitioners a rapid, objective method for assessing embryo viability that overcomes limitations associated with the current clinical practice of morphological examination. The selection of viable embryos is central to successful outcomes in IVF. The three studies to be presented at the ESHRE conference illustrate the accuracy of the Company's non-invasive metabolomic methodology compared to morphology, and will further support the commercialization of Molecular Biometrics' ViaTest-E technology."

Molecular Biometrics Presentations at ESHRE (Abstracts available upon request):

• In a podium presentation (0077 - Session 19: PGS/Embryo Selection Room: Pasteur Auditorium), Principal Investigators Carlijn Vergouw, M.Sc. and Dr. C.B. Lambalk (et. al.) of the Medical Centre, Reproductive Medicine, Amsterdam, the Netherlands, will present findings of a study titled, Near Infrared Spectroscopy as a tool to predict embryo viability: a novel, non-invasive method for embryo selection. This presentation will take place July 2, 2007 from 3:15 PM to 4:30 PM.

• In a poster presentation (# P 425) Principal Investigator, B. Behr (et. al.) of Stanford University, Department of Obstetrics and Gynecology, Stanford California, will present findings of a study titled, Identification of unique biomarkers of human oocyte maturation by non-invasive metabolomic profiling.

• In a podium presentation (0025 Session 05 - Embryology Room - Forum 2), Principal Investigator C.D. Skinner (et. al.) of Concordia University, Quebec, will present findings of a study titled, Albumin modification in culture media as a surrogate marker that is predictive of embryo viability. This presentation will take place, July 2nd, 2007 from 10:00 AM to 11:30 AM.

Molecular Biometrics' ViaTest-E is a non-invasive, point-of-care system that targets in vitro biomarkers of oxidative metabolism (OM) that are indicative of embryo viability. Complex interactions between the pro-oxidants and antioxidants are crucial in the maintenance of normal intracellular homeostasis. An imbalance in these reactions results in OM, which is known to affect the quality of spermatozoa, eggs and embryos.

The company's ViaTest-E System can enable identification and simultaneous analysis of multiple small molecule biomarkers of OM in a single sample. This analysis is expected to lead to the detection of viable embryos of high reproductive potential. Single use, disposable sample cells are used in conjunction with the Company's instrumentation.

The Company's metabolomics platform has also been applied to multiple other therapeutic applications, as well as in pharmacodiagnostics for drug discovery and development.

Advertisement